SG&A Expense Trends: Bio-Techne Corporation vs Exelixis, Inc.

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. Over the past decade, Bio-Techne Corporation and Exelixis, Inc. have shown significant shifts in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Bio-Techne's SG&A expenses surged by over 550%, reflecting strategic investments in growth and innovation. Meanwhile, Exelixis, Inc. experienced an even more dramatic increase of approximately 970%, peaking in 2023. This trend highlights Exelixis's aggressive expansion and market penetration strategies. Notably, the data for 2024 is incomplete, indicating potential changes in financial strategies or reporting. These insights provide a window into the operational priorities of these biotech giants, offering a glimpse into their future trajectories. As the industry evolves, monitoring such financial metrics will be key to understanding the competitive landscape.